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S U M M A R Y
Background: Blood stream infections (BSIs) due to carbapenem-resistant Enterobacteriaceae (CRE) are
associated with high hospital mortality rates and present a tremendous challenge to clinicians. The
optimal treatment remains undeﬁned. We aimed to investigate the risk factors for mortality and the
correlation between different treatment modalities and outcomes.
Methods: The clinical characteristics and treatment outcomes of a cohort of 36 patients with BSIs due to
CRE were investigated and a retrospective nested case–control study of surviving and non-surviving
patients was conducted.
Results: Fifty percent of the cases were male and the mean patient age was 54.9  15.8 years. Klebsiella
pneumoniae was the etiological agent in 26 cases (72.2%), Escherichia coli in eight (22.2%), and Enterobacter
aerogenes in two (5.5%). All strains were phenotypically positive for carbapenemase activity and all except
two (one E. coli and one K. pneumoniae) yielded both blaOXA-48 carbapenemases and blaCTX-M-type
extended-spectrum beta-lactamases (ESBLs) in PCR products. The 14-day, 28-day, and all-cause in-hospital
mortality rates were 41.6%, 50%, and 58.3%, respectively. The median time to death was 8 days (range 2–52
days). No signiﬁcant differences were observed between survivors and non-survivors in terms of baseline
characteristics, comorbid conditions, etiologies, or sources of bacteremia, however hematological
malignancies (p = 0.015) and prolonged neutropenia (p = 0.044) were more common in non-survivors.
Microbiological eradication and clinical response within 7 days were two major determinants of 28-day
attributable mortality (p = 0.001 and p = 0.001, adjusted r2 = 0.845). Colistin-based dual combinations, and
preferably triple combinations, were associated with signiﬁcantly better outcomes when compared to non-
colistin-based regimens (p < 0.001). Time to active treatment had a signiﬁcant effect on the course of
infection (p = 0.014).
Conclusion: Earlier active treatment with colistin based regimens and microbiological and clinical
response wthin 7 days are major predictors of survival in cases of BSIs due to CRE. Rectal screening offers
the advantage of earlier recognition and prompt empirical treatment.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Resistance to extended-spectrum cephalosporins is a well-
recognized problem among Enterobacteriaceae.1 Carbapenems
have served as an important antimicrobial class for the treatment
of these organisms and, until recently, resistance to carbapenems* Corresponding author. Tel.: +90 212 4143000 23066.
E-mail address: ilkerinancbalkan@hotmail.com (I.I. Balkan).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).has been uncommon among Enterobacteriaceae in Turkey. Following
the ﬁrst description of plasmid-encoded carbapenem-hydrolyzing
oxacillinase OXA-48 in 2004, the ﬁrst outbreak and subsequent
spread of carbapenem-resistant Klebsiella pneumoniae (CRKp) iso-
lates were reported from Turkey by the year 2008.2–6 Carbapenem-
resistant Enterobacteriaceae (CRE), some with low imipenem and
meropenem minimum inhibitory concentrations (MICs) (<4 mg/ml
according to the Clinical and Laboratory Standards Institute)
corresponding to susceptible or intermediate results, have contin-
ued to spread, disguised among extended-spectrum beta-lactamaseciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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recently, OXA-48-producers have spread in several countries of the
Middle East, North Africa, and Europe, with outbreaks.9
CRE, often resistant to all beta-lactam antibiotics and frequently
co-resistant to most other antibiotics, present a tremendous
challenge to the clinician.10 The optimal treatment remains
undeﬁned.11 Given the low expectations regarding new anti-
microbials, further investigations into existing treatment modali-
ties are urgently required.
In this study we aimed to investigate the clinical characteristics
and treatment outcomes of a cohort of 36 cases with blood stream
infections (BSIs) due to CRE, followed in a tertiary university
hospital in Istanbul, Turkey.
2. Patients and methods
2.1. Study design and data collection
The cases of patients diagnosed with BSIs due to CRE in
Cerrahpas¸ a Medical Faculty, a 1400-bed university hospital in
Istanbul, between February 2011 and March 2013, were reviewed.
A retrospective nested case–control study of 28-day survivors and
non-survivors was conducted. All data were extracted from
regular consultation records and the hospital database. The
primary end-point was 28-day survival, while secondary end-
points were 14-day survival and clinical and microbiological
responses at day 7.
All retrospective data were extracted from the hospital
database and consultation records, and approval of the local
ethics committee was not required. The conﬁdentiality of all data
was maintained.
2.2. Inclusion and exclusion criteria
Case patients were those with a CRE BSI (primary or secondary)
treated for at least 24 h with any antimicrobial or combination to
which the causative organism was found to be susceptible in vitro.
Inclusion criteria were the following: (1) BSI (bacteremia and
sepsis) due to CRE; (2) isolation of CRE from two or more separate
sets of blood cultures (peripheral veins and/or catheters); (3)
treatment with any antimicrobial regimen comprising one (for
monotherapy) or two or more (for combinations) drugs with in
vitro activity (the dosages and routes of administration being in
accordance with current medical recommendations); (4) the
treatment had to be started at the latest within 72 h relative to
the positive blood culture; (5) only the ﬁrst episode of CRE
bacteremia was included in the case of more than one bacteremic
episode due to the same pathogen; (6) any concomitant infection
(as is not unusual for intensive care unit (ICU) patients) should
have been treated appropriately and effectively.
Exclusion criteria were the following: (1) did not meet the
diagnostic criteria of CRE BSIs (in terms of resistance pattern and
case deﬁnition); (2) coincident with an ongoing episode of any
bacteremia (or polymicrobial growth in blood culture); (3)
duration <24 h of active treatment; (4) pregnancy; (5) age <18
years.
2.3. Microbiological methods and carbapenem resistance
An automated blood culture system (BD, USA) was used for
pathogen isolation and API ID 32 E automated test strips
(bioMe´rieux, France) were used for the identiﬁcation of Gram-
negatives, particularly Enterobacteriaceae. The disk diffusion
method (BBL Mueller Hinton II Agar and BBL Sensi-Disc
Susceptibility Test Disk ETP 10 mcg; BD, USA) was used for
antimicrobial susceptibility testing. The media were incubated at35–37 8C for 16–18 h. Gram-negatives found to be resistant to at
least one of the carbapenems by disk diffusion were further tested
by E-test method (bioMe´rieux) for deﬁnition as carbapenem-
resistant. Test results for both methods were evaluated in
accordance with the relevant European Committee on Antimicro-
bial Susceptibility Testing (EUCAST) recommendations.12 Rectal
screening for CRE was performed using an in-house prepared
chromogenic-based selective medium (HiCrome UTI agar + 4 mg/l
ertapenem; Himedia Laboratories, India); colonies of carbapenem-
resistant E. coli appear pink in color and carbapenem-resistant
Klebsiella spp appear blue.
2.4. Severity assessment scores
The severity of bacteremia was determined by Pitt bacteremia
score, which was calculated according to the following criteria: (1)
oral temperature (2 points for a temperature of 35 8C or 40 8C, 1
point for a temperature of 35.1–36.0 8C or 39.0–39.9 8C, and 0
points for a temperature of 36.1–38.9 8C); (2) hypotension (2
points for an acute hypotensive event with decreases in systolic
(>30 mmHg) and diastolic (>20 mmHg) blood pressures, use of
intravenous vasopressor agents, or a systolic blood pressure of
<90 mmHg); (3) mechanical ventilation (2 points); (4) cardiac
arrest (4 points); and (5) mental status (0 points for alert, 1 point
for disoriented, 2 points for stuporous, and 4 points for
comatose).13 Patients with scores >4 were considered critically
ill. The severity of the patient’s underlying diseases was
determined by Charlson comorbidity index, which contains 19
categories of comorbidity and predicts the 10-year mortality for a
patient who may have a range of comorbid conditions. Each
condition is assigned a score of 1, 2, 3, or 6 depending on the risk of
dying associated with that condition.14 This scoring system
replaces direct prospective measures of the severity of an illness
and is suitable for retrospective studies. Severity assessment
scores were used to evaluate and adjust the risk factors that have
an inﬂuence on the clinical judgment of the cases in both the
survivor and non-survivor groups in order to clarify the
attributable affect of antimicrobial regimens on the outcomes.
The Acute Physiology and Chronic Health Evaluation (APACHE II)
scores were not available for most cases and therefore were
not used.
2.5. Clinical and microbiological response
A clinical response at day 7 was deﬁned as partial or complete
recovery of symptoms, signs, and laboratory ﬁndings of infection.
This was basically determined by improvement in fever and white
blood cell counts in non-neutropenic patients. Signiﬁcant
decreases in C-reactive protein and procalcitonin levels were used
as markers of recovery from sepsis.
A microbiological response at day 7 was deﬁned as a negative
blood culture result on day 7 (control blood cultures were obtained
within the ﬁrst 48–72 h of treatment).
2.6. Molecular analysis
Conventional in-house PCR methods were used for the
detection of the bla genes; PCR test procedures were performed
in separate circumstances and negative controls were used for
each batch (Table 1). A rapid pulsed-ﬁeld gel electrophoresis
(PFGE) protocol developed by Durmaz et al. and banding pattern
interpretation according to the criteria of Tenover et al. were used
to identify clonal relationships between the 15 K. pneumoniae
isolates obtained from the hematology department.15,16 The
strains were evaluated to be indistinguishable, closely related,
possibly related, or different.
Table 1
Primer sequencesa
bla Primer Sequence Tm (8C) Accession number Position bp
blaVIM Pan_VIM_Fw TTCTCGCGGAGATTGARAAGC 54 JN819277 219–239 264
Pan_VIM_Rev TTGTCGGYYGAATGCGCAGC 483–464
blaIMP Pan_IMP_Fw GGAATAGAGTGGCTTAAYTCTC GU207399 372–393 188
Pan_IMP_Rev ARCCAAACYACTASGTTATC 50 560–543
blaOXA-48 OXA-48_Fw GCGTGTATTAGCCTTATCGGC JN626286 5518–5537 722
OXA-48_Rev RGGCATATCCATATTCATCGC 52 6240–6220
blaCTX-M CTXM_Fw ATCTGACGCTGGGTAAAGC JQ686201 695–713 162
CTXM_Rev ATATCGTTGGTGGTGCCATA 50 857–838
blaNDM NDM_Fw GGGCAGTCGCTTCCAACGGT 55 JQ734687 212–231 475
NDM_Rev GTAGTGCTCAGTGTCGGCAT 687–668
blaKPC KPC_Fw GCTGTCTTGTCTCTCATGGCC 55 JQ867396 394–414 836
KPC_Rev AATCCCTCGAGCGCGAGTCTA 1230–1210
a (1) Kucukbasmaci A, Midilli K, Issa G, Guven O, Gonullu N. A new multiplex PCR method for rapid detection of genes encoding VIM and IMP types of metallo beta
lactamases. Turkiye Klinikleri J Med Sci 2010;30:1312–6; (2) Lee SH, Jeong, SH, Lee KJ. Evolution of TEM b-lactamase genes identiﬁed by PCR with newly designed primers in
Korean clinical isolates. Clin Microbiol Infect 2001;7:98–100; (3) Davies TA, Queenan AM, Morrow BJ, Shang W, Amsler K, He W, et al. Longitudinal survey of carbapenem
resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007–09. J Antimicrob Chemother 2011;66:2298–307.
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SPSS 17.0 software (SPSS Inc., Chicago, IL, USA) was used for the
statistical analysis. Continuous variables were compared with the
Mann–Whitney U-test and categorical variables were compared
with the Pearson Chi-square test and Fisher’s exact test. Pearson
and Spearman correlation tests were performed in the ﬁrst step
analyses. Variables found to have signiﬁcant correlation coefﬁ-
cients (r > 0.150) were included in the linear regression analysis.
Odds ratios (ORs) and 95% conﬁdence intervals (CIs) were
estimated. All p-values were two-tailed, and a p-value of 0.05
was considered statistically signiﬁcant.Table 2
Patient characteristics
Total
(n = 36)
Demographics
Age, years, mean  SD 54.9  15.8 
Gender, male, n (%) 18 (50) 
Unit of hospitalization, n (%) 
Internal medicine 15 (41.6) 
Intensive care 14 (38.8) 
Surgical 7 (19.4) 
Hospital length of stay, mean  SD 71.8  52.1 
ICU admissionc, n (%) 26 (72.2) 
ICU length of stay, mean  SD 33.8  45.4 
Comorbidities, n (%)
Hematological malignancy 12 (33.3) 
Prolonged neutropeniad 11 (30.5) 
Solid tumor 15 (41.6) 
Chronic kidney disease 3 (8.3) 
Complicated diabetes 5 (13.8) 
Chronic pulmonary disease 1 (2.7) 
Neurological disease 6 (16.6) 
Cardiac disease 1 (2.7) 
Multiple trauma 1 (2.7) 
Charlson comorbidity index, mean  SD 2.3  1.6 
Pitt bacteremia score, mean  SD 3.8  3.8 
Risk factors, n (%)
Surgerye 11 (30.5) 
CVC 14 (38.8) 
CVC removal 6 (16.6) 
Mechanical ventilation 14 (38.8) 
Hemodialysis 2 (5.5) 
SD, standard deviation; ICU, intensive care unit; CVC, central venous catheter; NA, not a
stay); BSI, blood stream infection.
a Survivors and non-survivors at day 28.
b Univariate analysis.
c ICU admission at the time of or right after bacteremia.
d Neutropenia >10 days before BSI.
e Surgery within 30 days prior to bacteremia.3. Results
During the study period, a total of 36 patients (50% male, 50%
female) were identiﬁed with a CRE BSI; their median age was 59
(range 21–88) years. All cases fulﬁlled the inclusion criteria, except
for eight with only one set of positive blood cultures, of whom ﬁve
survived. No signiﬁcant differences were observed between
survivors and non-survivors in terms of baseline characteristics,
comorbid conditions, etiologies, and sources of bacteremia (Tables
2 and 3).
Hematological malignancies (p = 0.015) and prolonged neutro-
penia (p = 0.044) were more common in non-survivors. AlthoughSurvivorsa
(n = 18)
Non-survivorsa
(n = 18)
p-Valueb
56.2  15.6 53.5  16.4 0.606
9 (50) 9 (50) 1
0.6
6 (53) 9 (50)
8 (44) 6 (33)
4 (22) 3 (16)
70.8  47.2 71.85  63.9 0.854
8 (44.4) 18 (100) 0.0001
66.5  59 15.8  21.5 NA
4 (22.2) 8 (44.4) 0.015
4 (22.2) 7 (38.8) 0.044
9 (50) 6 (33.3) 0.471
0 3 (16.6) 0.5
3 (16.6) 2 (11.1) 0.229
1 (5.5) 0 1.0
3 (16.6) 3 (16.6) 1.0
0 1 (5.5) 1.0
1 (5.5) 0 1.0
2.61  1.9 2.06  1.11 0.307
3.00  3.5 4.56  4.0 0.231
7 (38.8) 4 (22.2) 0.471
8 (44.4) 6 (33.3) 0.367
3 (16.6) 3 (16.6) 1.0
8 (44.4) 6 (33.3) 0.367
0 2 (11.1) >0.05
pplicable (because of the association between overall survival and duration of ICU
Table 3
Etiologies and sources of bacteremia
Total
(n = 36)
Survivors
(n = 18)
Non-survivors
(n = 18)
p-Valuea
Etiology, n (%)
Klebsiella pneumoniae 26 (72.2) 12 (66.6) 14 (77.7) 0.341
Escherichia coli 8 (22.2) 4 (22.2) 4 (22.2)
Enterobacter aerogenes 2 (5.5) 2 (11.1) 0
Source of bacteremia, n (%) 0.189
Primary/central line 22 (61.1) 14 (38.8) 8 (22.2)
Intra-abdominal
(including SSI)
8 (22.2) 3 (8.3) 5 (13.8)
Pulmonary 2 (5.5) 0 2 (5.5)
CNS (SSI, shunt-related) 2 (5.5) 0 2 (5.5)
Urinary 2 (5.5) 1 (2.7) 1 (2.7)
SSI, surgical site infection; CNS, central nervous system.
a Univariate analysis.
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non-survivors (100% vs. 44.4%, p = 0.0001), prior ICU admission
rates (44% vs. 33%, p = 0.6) as a risk factor for developing CRE BSI
were not signiﬁcantly different between the two groups. The mean
duration of ICU stay was longer for survivors, but a statistical
analysis was not applicable because of the association between
overall survival and duration of ICU stay.
The 14-day, 28-day, and all-cause in-hospital mortality rates
were 41.6% (15/36), 50% (18/36), and 58.3% (21/36 patients),
respectively. The median time to death from the date of ﬁrst
positive culture was 8 days, ranging from 2 to 52 days.
Day 7 microbiological response and day 7 clinical response
were found to be two independent variables determining 85% in
total of 28-day mortality (p = 0.001, adjusted r2 = 0.845). Unre-
sponsiveness to treatment on day 7 was strongly correlated with a
failure of 28-day survival in this patient group. When these two
parameters were excluded in the linear and logistic regression
analyses, the presence of a high-risk hematological malignancy
(p = 0.015) and treatment with non-colistin-based combination
regimens (p < 0.001) were found to be independent variables
adversely affecting 28-day mortality. Three patients died between
day 14 and day 28. Two of these patients died on day 15 due to
complications of persistent bacteremia and sepsis. The third case
was extremely immunosuppressed due to aplastic anemia and he
died of persistent K. pneumoniae bacteremia after 24 days of
combined treatment based on relatively acceptable susceptibilities
to colistin, amikacin, and cefepime. Of the patients who survived
their hospitalization, 100% (15 of 15) were discharged home.
Patients were treated with the following antimicrobial classes,
alone or in various combinations: colistin (n = 24), aminoglyco-
sides (n = 21), carbapenems (n = 17), cephalosporins (n = 14), and
tigecycline (n = 6). Treatment modalities and outcomes are shown
in Table 4.
Five patients died before cultures were ﬁnalized, two of whom
were switched to imipenem prior to the blood culture results;Table 4
Treatment outcomes
Total
(n = 36)
Time to active treatment, days, mean  SD 1.25  1.32 
Duration of treatment, days, mean  SD 14.58  16.015 
Treatment modalities
Colistin dual combination (n = 12) 12 (33.3) 
Colistin triple combination (n = 12) 12 (33.3) 
Non-colistin based combinations (n = 7) 7 (19.4) 
Carbapenem monotherapy (n = 5) 5 (13.8) 
a Univariate analysis.
b Duration of treatment is naturally longer in survivors.another was on imipenem and amikacin combination treatment
and the last two were switched to colistin-based combinations
empirically after blood cultures were obtained. Three patients
were treated successfully with carbapenem monotherapy (two
imipenem and one meropenem). Due to the early and prompt
clinical response to empirical treatment, carbapenem was main-
tained despite high MICs for ertapenem (>2 mg/ml) indicating in
vitro resistance. Treatment success was probably attributable to
catheter removal in the ﬁrst case and to the earlier source control
with surgery in the other two.
Seven cases received non-colistin-based combinations. Two
had previously experienced acute renal failure due to colistin use,
one had died before culture results were ﬁnalized, and colistin was
not available for the other four. The rate of 28-day survival was
signiﬁcantly lower in cases treated with non-colistin-based
combinations (5.5% vs. 33.3%; p = 0.018).
Survival rates were not signiﬁcantly different among the three
subgroups of dual colistin combinations: colistin plus carbapenem,
colistin plus aminoglycoside, and colistin plus cephalosporins
(p > 0.05). Patients treated with colistin dual combinations
(n = 12) had lower survival rates (38% vs. 75%) when compared
to those who received colistin triple combinations (n = 12).
Colistin–aminoglycoside–cephalosporin (six ceftazidime and three
cefepime) was the most common triple colistin combination, used
in nine patients.
3.1. Molecular analysis of the outbreak of six cases due to OXA-48-
producing K. pneumoniae
Clonal relationships between 15 K. pneumoniae isolates, those
isolated from blood cultures of febrile neutropenia cases followed
in the hematology unit, were investigated by pulsed-ﬁeld gel
electrophoresis (PFGE). DNA band proﬁles of the ﬁrst six isolates of
K. pneumoniae isolated between February 2011 and May 2012 (the
ﬁrst four cases occurring in February 2011) were identical,
indicating an ongoing outbreak caused by a single strain
(Figure 1). No signiﬁcant source of bacteremia was detected
in the investigation conducted by the hospital infection control
committee (HICC). The latter nine isolates were not related to
the former six, although all had OXA-48-type carbapenemases
and CTX-M-type ESBLs. The outbreak was brought under control
after the application of strict measures including an effective
education program on contact isolation precautions and
weekly rectal screening. All strains were phenotypically
positive for carbapenemase activity and all except two (one
E. coli and one K. pneumoniae) yielded both blaOXA-48 carbapene-
mases and blaCTX-M-type ESBLs in PCR products. VIM-5-type
metallo-beta-lactamase was detected in the aforementioned
K. pneumoniae strain and no beta-lactamase-encoding gene was
detected by our panel in the E. coli strain, for which carbapenem
resistance was attributed to overexpression of ESBLs combined with
porin defects.Survivors
(n = 18)
Non-survivors
(n = 18)
p-Valuea
0.72  1.18 1.78  1.26 0.014
22.72  18.68 6.44  6.21 0.002b
5 (27.7) 7 (38.8) 0.725
9 (50) 3 (16.6) 0.075
1 (5.5) 6 (33.3) 0.018
3 (16.6) 2 (11.1) 1
Figure 1. PFGE results for six Klebsiella pneumoniae strains.
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Over the last 10 years, patients hospitalized in high-risk units
(ICUs, hemato-oncology wards, and burn units) have been
screened weekly for rectal colonization by vancomycin-resistant
enterococci (VRE), in accordance with a policy of the HICC. Active
surveillance with regular weekly rectal screening for CRE (CRKp
and carbapenem-resistant E. coli) colonization was started after
the outbreak in the hematology unit and ICUs in May 2012, in
addition to the core prevention measures implemented by the
HICC based on the newly published editorial by Nordmann and
Cornaglia and the updated recommendations of the US Centers for
Disease Control and Prevention (CDC).17,18 A total of 884 patients
were screened during the study period, 124 of whom were found to
be colonized with CRE (hematology 24/167, ICUs 100/717), and 13
of the 36 cases with BSIs presented here were detected as
colonized prior to bacteremia. Eight (61.5%) of these patients
survived and ﬁve (38.5%) died within 28 days. Three of those who
survived (3/8) and two of those who did not survive (2/5) had high-
risk hematological malignancies.
4. Discussion
CRE infections have become a major concern worldwide,
particularly in healthcare settings.19,20 Reported risk factors for
infection with CRE are similar to risk factors associated with ESBL-
producing Enterobacteriaceae.21 Patients in our cohort were both
chronically ill (as shown by the mean Charlson comorbidity index
of 2.3  1.6) and acutely ill (as evident by the high Pitt bacteremia
scores, with a mean of 3.8  3.8).
CRE infections are associated with both high morbidity and
mortality. The overall hospital mortality of 58.3% and 28-day
attributable mortality of 50% determined in our study are
consistent with those of previous reports. In a series of CRKp BSIs
(n = 32), Borer et al. reported crude and attributable mortality rates
of 71.9% and 50%, respectively.22 In a New York City outbreak of 19
patients with BSIs due to CRKp, 14-day mortality was reported as
47%.23 The overall crude mortality rate was reported to be 39.0%
(16/41) in another series of 41 BSIs due to CRKp from the USA.24Awareness of risk factors for CRE BSIs is important in order to
reduce the time to appropriate treatment. There was a signiﬁcant
difference in time to active therapy between groups in our study,
and the delay in appropriate therapy may, in part, explain the high
mortality rate. Prolonged neutropenia in those with hematological
malignancies was a highly signiﬁcant variable contributing to
worse outcomes, particularly when persistent after the BSI had
emerged.
In terms of treatment response, microbiological eradication and
clinical improvement on day 7 were found to be two major indicators
of 28-day survival, consistent with the study of Nguyen et al.25
Clinically, a very limited number of antimicrobial options
remain for the treatment of CRE BSIs. There is clear evidence
against monotherapy.26 Various combinations are under re-
search.27 Colistin-based combined antimicrobial regimens have
become the backbone of treatment, while the optimal combination
remains unknown.24,27,28 Qureshi et al. reported that the most
common successful combination for treating Klebsiella pneumo-
niae carbapenemase (KPC) infections is colistin with either
tigecycline or a carbapenem.24 Tumbarello et al. demonstrated
that a triple-drug regimen including tigecycline, colistin, plus a
carbapenem, was independently associated with improved sur-
vival in KPC infections.29 Likewise, in a series of 55 individual cases,
combination therapy was associated with successful outcomes
compared to monotherapy, particularly if colistin was part of the
regimen.30 Pooled data of 215 patients with BSIs due to CRE
followed in Greek hospitals between 2004 and 2011 revealed that
the overall success rate of combination therapy was signiﬁcantly
higher than that of monotherapy (p = 0.01; OR 2.41, 95% CI 1.2–
4.7). Carbapenem-containing combination therapies with two or
more active drugs (colistin the most common) showed a
signiﬁcantly higher success rate when compared to non-carbape-
nem-containing regimens (93.3%; p = 0.04; OR 5.15, 95% CI 1.1–
24.5). Colistin was reported to be the least effective agent in the
monotherapy group in the same study.20
Colistin was not used as monotherapy in any case in our cohort.
Non-colistin-based combinations, which were used basically for
those who were expected to be intolerant or for whom colistin was
unavailable at that time, were found to be related to the poorest
outcomes.
Although carbapenem-based treatments are suggested for
treating infections caused by OXA-48-producers remaining within
the susceptibility ranges in vitro, due to the high rate of previous or
ongoing carbapenem exposure in 75% of our cases, carbapenems
were preferred in only six dual combinations and none of the triple
combinations.9
Based on previous reports regarding OXA-48, the dominant
type of carbapenemase among K. pneumoniae isolates in Turkey,
and due to their relative and partial susceptibilities to oxyimino-
cephalosporins, ceftazidime or cefepime was included in the triple
combined treatment of 14 cases.2,6 Despite a lack of clear evidence,
treatments based on broad-spectrum cephalosporins could be
used safely when facing infections caused by ESBL-negative OXA-
48-producers.9 Considering the very high incidence (94.4%) of
CTX-M-type ESBL co-resistance in our strains, looking retrospec-
tively, it should be admitted that no beneﬁt would be expected
with cephalosporin combinations. However, the use of triple
combinations of colistin (colistin–aminoglycoside–ceftazidime/
cefepime being the most common) was associated with slightly
better 28-day survival outcomes when compared to colistin dual
combinations (p = 0.075).
Determining which antimicrobial is superior for combination
remains to be established in further clinical studies.
After the implementation of rectal screening for CRE, owing to
the awareness and earlier effective empirical treatment of sepsis in
colonized patients, 28-day mortality decreased from 83% (5/6) to
I.I. Balkan et al. / International Journal of Infectious Diseases 26 (2014) 51–565640% (2/5) after May 2012 in the patients with high-risk
hematological cancers. Of course this decline is not attributable
only to the screening factor; a rapid recovery from profound
neutropenia after BSI was the basic common feature of those who
survived. Nonetheless, screening keeps the clinicians one step
ahead in terms of preventing transmission, as proper contact
precautions can be implemented and effective antimicrobial
combinations planned in advance for those cases who go on to
develop fever.
Another important measure that should be noted to prevent
emerging CRE infections would be ‘carbapenem-sparing empirical
treatment’ by combining non-carbapenem anti-pseudomonal
beta-lactam agents with amikacin within the context of a de-
escalation approach in settings with a high risk of ESBL.31
The limitations of our study are inherent to its retrospective
design and the relatively limited number of occurrences of this
disease. Measures to compare the efﬁcacies of the various
regimens are extremely limited, since the treatment regimens in
our cohort were not assigned randomly. Dosing practices,
particularly regarding colistin doses, were not standard. Likewise,
owing to the frequent alterations in the clinical status of these
critically ill patients, antibiotic regimens were often modiﬁed
during treatment. Therefore, it is rather difﬁcult to correlate the
durations and outcomes.
In conclusion, BSIs due to CRE are more common in patients
with severe comorbidities, particularly those with hematological
malignancies; they are associated with high hospital mortality
rates, regardless of treatment modalities. Microbiological and
clinical responses within the ﬁrst 7 days of treatment are major
determinants of 28-day attributable mortality. Colistin-based dual
combinations, and preferably triple combinations, are associated
with signiﬁcantly better outcomes when compared to non-
colistin-based regimens. Time to active treatment has a signiﬁcant
effect on the course of infection, and rectal screening offers the
advantage of earlier recognition and prompt empirical treatment
of CRE BSIs.
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